A Phase 1 interventional study of LOXO-783 and Fulvestrant in Breast Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 50 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
How we know · 14 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 21st largest by planned enrollment of the 80 interventional ones that give a count, is one of 4 that started in 2022, is one of 17 in phase 1, reaches primary completion later than 13 of the 21 other live ones, and was the 79th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, France and 4 more countries
Ages 18+ · Women only
Eli Lilly and Company · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, China, Germany and 2 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 16 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 138 across the 80 interventional studies. Of the 61 that completed or were terminated, 40 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 542 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
1 of the studies in Breast Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have
--- Patients with non-breast tumor types must have at least 1 measurable lesion
For patients with an estrogen receptor (ER)+ breast cancer diagnosis:
Phase 1a:
-- Dose escalation and backfill patients:
Phase 1b:
Part A:
Part B:
Part C:
Patients may have had up to 5 prior regimens for advanced disease.
---- Prior CDK4/6 inhibitor therapy required.
Part D:
Part E:
Part F:
Patients may have had up to 5 prior regimens for advanced disease
Exclusion Criteria:
Medical Conditions
A history of known active or suspected
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LOXO-783 administered orally
Drug: LOXO-783
LOXO-783 administered orally in combination with fulvestrant intramuscularly, imlunestrant orally, or an aromatase inhibitor orally
Drug: LOXO-783 · Drug: Fulvestrant · Drug: Imlunestrant · Drug: Anastrozole, Exemestane, or Letrozole
LOXO-783 orally in combination with abemaciclib and either physician's choice aromatase inhibitor orally, fulvestrant intramuscularly, or imlunestrant orally
Drug: LOXO-783 · Drug: Fulvestrant · Drug: Imlunestrant · Drug: Abemaciclib · Drug: Anastrozole, Exemestane, or Letrozole
LOXO-783 orally in combination with fulvestrant intramuscularly
Drug: LOXO-783 · Drug: Fulvestrant
LOXO-783 orally in combination with paclitaxel intravenously
Drug: LOXO-783 · Drug: Paclitaxel
LOXO-783 orally
Drug: LOXO-783
Multiple randomized dose levels of LOXO-783 orally with fulvestrant intramuscularly
Drug: LOXO-783 · Drug: Fulvestrant
Oral
Also known as: LY3849524
Intramuscular
Oral
Also known as: LY3484356
Oral
Also known as: LY2835219
Oral
Intravenous
This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Phase 1 a: To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of LOXO-783: Number of patients with dose-limiting toxicities (DLTs)
Number of patients with DLTs
Time frame: During the first 28-day cycle of LOXO-783 treatment
Phase 1 a: To determine the MTD/RP2D of LOXO-783: Number of patients with DLT-equivalent toxicities
Number of patients with DLT-equivalent toxicities
Time frame: During the first 28-day cycle of LOXO-783 treatment
To assess the pharmacokinetics (PK) of LOXO-783: Area under the concentration versus time curve (AUC)
PK of LOXO-783: AUC
Time frame: Up to 2 months
To assess the PK of LOXO-783: Maximum drug concentration (Cmax)
PK of LOXO-783: Cmax
Time frame: Up to 2 months
To evaluate the preliminary antitumor activity of LOXO-783: Overall response rate (ORR)
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Best overall response (BOR)
BOR per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Duration of response (DOR)
DOR per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Disease control rate (DCR)
DCR per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Clinical benefit rate (CBR)
CBR per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Time to response (TTR)
TTR per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Progression free survival (PFS)
PFS per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
To evaluate the preliminary antitumor activity of LOXO-783: Overall survival (OS)
OS per investigator assessed RECIST 1.1
Time frame: Up to approximately 36 months or 3 years
Plan to share: No
Ran from May 2022 to primary completion in Apr 2025, 34 months.
Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 34 months is below that.
Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Apr 2025, on Oct 14, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783